TNF and metabolic dysfunction-associated steatotic liver disease: Conversely, in a cross-sectional study by Likhitsup et al. including 80 IBD patients under treatment with TNFα agents, the authors, assuming a general prevalence of 30%, observed a significantly higher prevalence of NAFLD in these patients (p < 0.001), but they did not find any associations between disease duration and NAFLD [21].